8-K current report · filed Jul 14, 2026

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) 8-K Current Report: July 14, 2026

Item 1.01Item 1.02Item 2.02Item EX-99.1Item 2.03KMTS overview

Short answer

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item 2.03 (Creation of a Direct Financial Obligation). $75.0M Tranche A funded July 10, 2026, refinancing prior debt and leaving approximately $20.0M for corporate and working capital.

KESTRA MEDICAL TECHNOLOGIES, LTD. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $75.0M Tranche A funded July 10, 2026, refinancing prior debt and leaving approximately $20.0M for corporate and working capital
  • Total facility up to $200.0M through 2031, including $75.0M funded and $125.0M contingent or acquisition capacity
  • Variable interest rate: 5.50% plus three-month SOFR, with a 3.25% SOFR floor, increasing exposure to rates
  • 48 months interest-only, followed by four equal quarterly amortization payments beginning fiscal Q2 2030
  • Substantially all assets, including intellectual property, secure the debt; $20.0M minimum liquidity covenant constrains cash deployment

Item 1.02 · Termination of a Material Definitive Agreement

  • Prior Loan Agreement with Perceptive Credit Holdings IV terminated upon July 10, 2026 Loan Agreement
  • Borrower’s payment and other obligations fully paid and discharged
  • Prior Lender’s security interests in company assets and property released
  • Refinancing removed the prior lender’s claims against company collateral

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal quarter ended April 30, 2026 results announced on July 14, 2026
  • Exhibit 99.1 contains the detailed financial results and management commentary

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 links to Item 1.01, indicating a material financial obligation arose under the related agreement
  • Investors should review Item 1.01 for the obligation’s amount, payment terms, maturity, and business purpose

Item EX-99.1 · Exhibit EX-99.1

  • FY26 revenue $95.1M, up 59%, with ASSURE prescriptions up 57% to 20,720
  • Gross margin expanded to 51.4% from 40.5%, signaling improving unit economics and reimbursement mix
  • FY26 GAAP net loss widened to $131.6M, while adjusted EBITDA loss increased to $87.0M
  • Cash, cash equivalents, and investments totaled $262.2M, but operating cash use reached $81.7M
  • FY27 revenue guidance of $137M implies 44% growth, raising execution expectations for commercial expansion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other KESTRA MEDICAL TECHNOLOGIES, LTD. 8-K filings

Get the next KMTS 8-K as it lands

Follow KMTS for push alerts, or ask the research agent what this filing means.